- Home
- JKS vs TRML Comparison
JKS vs TRML Comparison
Compare JKS & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKS
- TRML
- Stock Information
- Founded
- JKS 2006
- TRML 2021
- Country
- JKS China
- TRML United States
- Employees
- JKS N/A
- TRML N/A
- Industry
- JKS Semiconductors
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- JKS Technology
- TRML Health Care
- Exchange
- JKS Nasdaq
- TRML Nasdaq
- Market Cap
- JKS 1.2B
- TRML 1.2B
- IPO Year
- JKS 2010
- TRML N/A
- Fundamental
- Price
- JKS $21.53
- TRML $47.98
- Analyst Decision
- JKS Sell
- TRML Hold
- Analyst Count
- JKS 4
- TRML 12
- Target Price
- JKS $28.99
- TRML $47.04
- AVG Volume (30 Days)
- JKS 575.6K
- TRML 655.6K
- Earning Date
- JKS 11-17-2025
- TRML 11-13-2025
- Dividend Yield
- JKS 6.96%
- TRML N/A
- EPS Growth
- JKS N/A
- TRML N/A
- EPS
- JKS N/A
- TRML N/A
- Revenue
- JKS $11,445,691,729.00
- TRML N/A
- Revenue This Year
- JKS N/A
- TRML N/A
- Revenue Next Year
- JKS $31.06
- TRML N/A
- P/E Ratio
- JKS N/A
- TRML N/A
- Revenue Growth
- JKS N/A
- TRML N/A
- 52 Week Low
- JKS $13.42
- TRML $11.56
- 52 Week High
- JKS $29.80
- TRML $48.27
- Technical
- Relative Strength Index (RSI)
- JKS 38.07
- TRML 90.41
- Support Level
- JKS $20.97
- TRML $47.88
- Resistance Level
- JKS $23.72
- TRML $48.00
- Average True Range (ATR)
- JKS 1.10
- TRML 0.05
- MACD
- JKS -0.31
- TRML -0.81
- Stochastic Oscillator
- JKS 11.52
- TRML 89.19
About JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.